Mutations of FLT3 are found in approximately 30% of newly diagnosed AML patients and appear either as ITDs (≈ 25%) or point mutations in the tyrosine kinase domain (TKD) (7–10%)4. Here, FLT3 is linked to acute myeloid leukemia.